Physician profile
Uma S Alampur
NPI 1457348393
$5,517.98
in general payments reported to CMS, 2019-2025
22 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $455 · 2021: $1,111 · 2022: $1,435 · 2023: $799 · 2024: $1,289 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.99 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Biogen, INC. | $1,053.49 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Alexion Pharmaceuticals, INC. | $690.58 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $601.25 | 2020-2024 | Emgality |
| Argenx US, INC. | $459.64 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $413.14 | 2020-2022 | |
| Pfizer INC. | $349.62 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $198.74 | 2019-2023 | Xarelto |
| Allergan, INC. | $152.07 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $96.17 | 2022 | |
| Eisai INC. | $64.49 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $58.45 | 2021 | |
| Sk Life Science, INC. | $54.49 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $31.14 | 2020-2024 | |
| Horizon Therapeutics Plc | $28.42 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $23.10 | 2021 | |
| Ucb, INC. | $22.14 | 2024 | Zilbrysq |
| Amgen INC. | $16.94 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.57 | 2021 | |
| Therapeuticsmd, INC. | $15.42 | 2021 | |
| Tanabe Pharma America, INC. | $14.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Alampur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.